Enhabit, Inc. Proxy Statement Filed

Ticker: EHAB · Form: DEFA14A · Filed: May 23, 2024

Sentiment: neutral

Topics: proxy-statement, regulatory-filing, corporate-governance

TL;DR

Enhabit proxy filing dropped. Standard corp stuff, formerly Encompass Health Home Health.

AI Summary

Enhabit, Inc. filed a DEFA14A proxy statement on May 23, 2024. This filing is a solicitation of proxies related to the company's business. Enhabit, Inc. was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name on February 18, 2020. The company is headquartered in Dallas, Texas.

Why It Matters

This filing is a standard regulatory document that provides shareholders with information necessary to vote on company matters, impacting corporate governance and shareholder rights.

Risk Assessment

Risk Level: low — This is a routine regulatory filing (DEFA14A) and does not contain new financial information or strategic decisions that would immediately impact stock price.

Key Players & Entities

Enhabit, Inc. (company) — Registrant
Encompass Health Home Health Holdings, Inc. (company) — Former company name
20240523 (date) — Filing date
0001803737-24-000070 (filing_id) — Accession Number

FAQ

What is the purpose of a DEFA14A filing?

A DEFA14A filing, also known as a definitive proxy statement, is used by companies to solicit proxies from shareholders for an upcoming meeting, providing them with information to vote on company matters.

When was this DEFA14A filed by Enhabit, Inc.?

Enhabit, Inc. filed this DEFA14A on May 23, 2024.

What was Enhabit, Inc.'s former name?

Enhabit, Inc. was formerly known as Encompass Health Home Health Holdings, Inc.

On what date did the company change its name?

The company changed its name from Encompass Health Home Health Holdings, Inc. to Enhabit, Inc. on February 18, 2020.

Where is Enhabit, Inc. headquartered?

Enhabit, Inc. is headquartered at 6688 N. Central Expressway, Suite 1300, Dallas, TX 75206.

Filing Stats: 3,140 words · 13 min read · ~10 pages · Grade level 17.3 · Accepted 2024-05-23 16:35:28

Key Financial Figures

$11 — provided indicative valuation ranges of $11 to $12 per share. One strategic acquiro
$12 — d indicative valuation ranges of $11 to $12 per share. One strategic acquiror provi
$10 — ategic acquiror provided a valuation of $10 per share. The other strategic acquiror

Filing Documents

a5232024defa14a-solicitati.htm (DEFA14A) — 42KB
0001803737-24-000070.txt ( ) — 43KB